Reducing expression of the protein ataxin-2 improved symptoms in mouse models of both spinocerebellar ataxia type 2 (SCA-2) and amyotrophic lateral sclerosis (ALS), scientists reported this week. Their findings appeared in two back-to-back papers in the April 13, 2017 issue of Nature.